Now showing items 1-13 of 13

    • Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. 

      Rini, BI; Dorff, TB; Elson, P; Rodriguez, CS; Shepard, D; Wood, L; Humbert, J; Pyle, L; Wong, Y-N; Finke, JH; Rayman, PA; Larkin, JMG; Garcia, JA; Plimack, ER (2016-09)
      A subset of patients with metastatic renal-cell carcinoma show indolent growth of metastases. Because of the toxicity and non-curative nature of systemic therapy, some of these patients could benefit from initial active ...
    • Analgesic Use and Ovarian Cancer Risk: An Analysis in the Ovarian Cancer Cohort Consortium. 

      Trabert, B; Poole, EM; White, E; Visvanathan, K; Adami, H-O; Anderson, GL; Brasky, TM; Brinton, LA; Fortner, RT; Gaudet, M; Hartge, P; Hoffman-Bolton, J; Jones, M; Lacey, JV; Larsson, SC; Mackenzie, GG; Schouten, LJ; Sandler, DP; O'Brien, K; Patel, AV; Peters, U; Prizment, A; Robien, K; Setiawan, VW; Swerdlow, A; van den Brandt, PA; Weiderpass, E; Wilkens, LR; Wolk, A; Wentzensen, N; Tworoger, SS; Ovarian Cancer Cohort Consortium (OC3) (2019-02)
      BACKGROUND:Aspirin use is associated with reduced risk of several cancers. A pooled analysis of 12 case-control studies showed a 10% decrease in ovarian cancer risk with regular aspirin use, which was stronger for daily ...
    • Characterizing genetic variants for clinical action. 

      Ramos, EM; Din-Lovinescu, C; Berg, JS; Brooks, LD; Duncanson, A; Dunn, M; Good, P; Hubbard, TJP; Jarvik, GP; O'Donnell, C; Sherry, ST; Aronson, N; Biesecker, LG; Blumberg, B; Calonge, N; Colhoun, HM; Epstein, RS; Flicek, P; Gordon, ES; Green, ED; Green, RC; Hurles, M; Kawamoto, K; Knaus, W; Ledbetter, DH; Levy, HP; Lyon, E; Maglott, D; McLeod, HL; Rahman, N; Randhawa, G; Wicklund, C; Manolio, TA; Chisholm, RL; Williams, MS (2014-03-13)
      Genome-wide association studies, DNA sequencing studies, and other genomic studies are finding an increasing number of genetic variants associated with clinical phenotypes that may be useful in developing diagnostic, ...
    • Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. 

      Merker, JD; Oxnard, GR; Compton, C; Diehn, M; Hurley, P; Lazar, AJ; Lindeman, N; Lockwood, CM; Rai, AJ; Schilsky, RL; Tsimberidou, AM; Vasalos, P; Billman, BL; Oliver, TK; Bruinooge, SS; Hayes, DF; Turner, NC (2018-06)
      Purpose Clinical use of analytical tests to assess genomic variants in circulating tumor DNA (ctDNA) is increasing. This joint review from ASCO and the College of American Pathologists summarizes current information about ...
    • Circulating tumor DNA-From bench to bedside. 

      Lim, JSJ; Janku, F; Yap, TA (2017-05)
      In the era of personalized medicine, tumor sampling is paramount to enable the assessment of actionable molecular aberrations to help rationalize and guide treatment decisions. Longitudinal tracking of such aberrations may ...
    • Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients. 

      Farag, S; Somaiah, N; Choi, H; Heeres, B; Wang, W-L; van Boven, H; Nederlof, P; Benjamin, R; van der Graaf, W; Grunhagen, D; Boonstra, PA; Reyners, AKL; Gelderblom, H; Steeghs, N (2017-05)
      Patients, platelet-derived growth factor receptor alpha (PDGFRA) D842V-mutated gastrointestinal stromal tumours (GISTs) are known for their insensitivity to imatinib. However, in clinical practice responses have been ...
    • A comprehensive map of molecular drug targets. 

      Santos, R; Ursu, O; Gaulton, A; Bento, AP; Donadi, RS; Bologa, CG; Karlsson, A; Al-Lazikani, B; Hersey, A; Oprea, TI; Overington, JP (2017-01)
      The success of mechanism-based drug discovery depends on the definition of the drug target. This definition becomes even more important as we try to link drug response to genetic variation, understand stratified clinical ...
    • Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. 

      Grob, JJ; Schadendorf, D; Lorigan, P; Ascierto, P; Larkin, J; Nathan, P; Robert, C; Hauschild, A; Weber, J; Daud, A; Hamid, O; Dummer, R; Hansson, J; Hoeller, C; Schachter, J; Van Akkooi, ACJ; Garbe, C (2018-03)
    • The National Cancer Institute Cohort Consortium: An International Pooling Collaboration of 58 Cohorts from 20 Countries. 

      Swerdlow, AJ; Harvey, CE; Milne, RL; Pottinger, CA; Vachon, CM; Wilkens, LR; Gapstur, SM; Johansson, M; Weiderpass, E; Winn, DM (2018-11)
      Cohort studies have been central to the establishment of the known causes of cancer. To dissect cancer etiology in more detail-for instance, for personalized risk prediction and prevention, assessment of risks of subtypes ...
    • Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer. 

      Moreno, L; Casanova, M; Chisholm, JC; Berlanga, P; Chastagner, PB; Baruchel, S; Amoroso, L; Gallego Melcón, S; Gerber, NU; Bisogno, G; Fagioli, F; Geoerger, B; Glade Bender, JL; Aerts, I; Bergeron, C; Hingorani, P; Elias, I; Simcock, M; Ferrara, S; Le Bruchec, Y; Slepetis, R; Chen, N; Vassal, G (2018-09)
      BACKGROUND:nab-Paclitaxel has demonstrated efficacy in adults with solid tumours and preclinical activity in paediatric solid tumour models. Results from phase I of a phase I/II study in paediatric patients with ...
    • The Premenopausal Breast Cancer Collaboration: A Pooling Project of Studies Participating in the National Cancer Institute Cohort Consortium. 

      Nichols, HB; Schoemaker, MJ; Wright, LB; McGowan, C; Brook, MN; McClain, KM; Jones, ME; Adami, H-O; Agnoli, C; Baglietto, L; Bernstein, L; Bertrand, KA; Blot, WJ; Boutron-Ruault, M-C; Butler, L; Chen, Y; Doody, MM; Dossus, L; Eliassen, AH; Giles, GG; Gram, IT; Hankinson, SE; Hoffman-Bolton, J; Kaaks, R; Key, TJ; Kirsh, VA; Kitahara, CM; Koh, W-P; Larsson, SC; Lund, E; Ma, H; Merritt, MA; Milne, RL; Navarro, C; Overvad, K; Ozasa, K; Palmer, JR; Peeters, PH; Riboli, E; Rohan, TE; Sadakane, A; Sund, M; Tamimi, RM; Trichopoulou, A; Vatten, L; Visvanathan, K; Weiderpass, E; Willett, WC; Wolk, A; Zeleniuch-Jacquotte, A; Zheng, W; Sandler, DP; Swerdlow, AJ (2017-09)
      Breast cancer is a leading cancer diagnosis among premenopausal women around the world. Unlike rates in postmenopausal women, incidence rates of advanced breast cancer have increased in recent decades for premenopausal ...
    • Ultrasound emissions: thermal and mechanical indices. 

      Kollmann, C; ter Haar, G; Doležal, L; Hennerici, M; Salvesen, KÅ; Valentin, L (2013-10)